3Bradford P A. Tigecycline: a first in class glycylcycline [J]. Clin Microbiol Newslett, 2004, 26. 163
4Boucher H W, Wennersten C B, Eliopoulos G M. In vitro activities of the glycylcycline GAR - 936 against gram - positive bacteria [J]. Antimicrob Agents Chemother, 2000, 44 (8) : 2225
5Edlund C, Nord C E. In vitro susceptibility of anaerobic bacteria to GAR - 936, a new glycylcycline [J]. Clin Microbiol Infect, 2000, 6 (3): 159
6Gales A C, Jones R N. Antimicrobial activity and spectrum of the new glycylcycline, OAR- 936 tested against 1,203 recent clinical bacterial isolates [J]. Diagn Microbiol Infect Dis, 2000, 36 (1): 19
7Jacobus N V, MclDermott L A, Ruthazer R, et al. In vitro activities of tigecycline against the Bacteroides fragilis group [J]. Antimicrob Agents Chemother, 2004, 48 (3):1034
8Milatovic D, Schrnitz F J, Verhoef J, et al. Activities of the glycylcycline tigecycline (GAR - 936) against 1, 924 recent European clinical bacterial isolates [J]. Antimicrob Agents Chemother, 2003, 47 (1): 400
9Petersen P J, Jaeobus N V, Weiss W J, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9 - tbutylglycylamido derivative of minocycline (GAR - 936) [J]. Antimicrob Agents Chemother, 1999, 43 (4): 738
10Cercenado E, Cercenado S, Gomez J A, et al. In vitro activity of tigecycline (GAR- 936), a novel glycylcycline, against vancomycin resistant enterococci and staphylococci with diminished susceptibility to glycopeptides [J]. J Antimicrob Chernother, 2003, 52 (1): 138
